Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.57 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.56 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10118075 | 1.00 | HPGD (0.76) | HPGDPAX8LMNATP53CYP2C19 | |
| SCHEMBL16787414 | 1.00 | HPGD (0.76) | HPGDPAX8LMNATP53CYP2C19 | |
| SCHEMBL14440590 | 0.99 | HPGD (0.74) | HPGDPAX8LMNATP53CYP2C19 | |
| SCHEMBL9945536 | 0.91 | HPGD (0.64) | HPGDPAX8LMNATP53CYP2C19 | |
| SCHEMBL12899836 | 0.91 | HPGD (0.63) | HPGDPAX8IMPDH2IMPDH1NT5E | |
| SCHEMBL16787416 | 0.90 | HPGD (0.62) | HPGDPAX8IMPDH2IMPDH1NT5E | |
| Guanosine SCHEMBL24049416 | 0.86 | HPGD (0.76) | HPGDPAX8LMNAADORA3NT5E | |
| Guanosine SCHEMBL24049417 | 0.86 | HPGD (0.76) | HPGDPAX8LMNAADORA3NT5E | |
| Guanosine SCHEMBL278157 | 0.86 | HPGD (0.76) | HPGDPAX8LMNAADORA3NT5E | |
| Guanosine SCHEMBL24049467 | 0.86 | HPGD (0.76) | HPGDPAX8LMNAADORA3NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149888-A1 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | CHEMGENES CORPORATION | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149888-A1 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS | TYMP, MTAP, GART | HPGD 3698/4885PAX8 3350/4885LMNA 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.